Polyadenylic-polyuridylic acid enhances the natural cell-mediated cytotoxicity in patients with breast cancer undergoing mastectomy.
BACKGROUND
Surgical procedures suppress host antitumor defense mechanisms, which may increase the risk of metastatic tumor dissemination. We have evaluated the effects of the biologic response modifier polyadenylic-polyuridylic acid (PAPU) on natural cytotoxicity in patients with breast cancer undergoing operation.


METHODS
PAPU (150 mg) or placebo was given intravenously during the perioperative period (preoperative, days -1 and 0; postoperative, days 1, 3, 5, 7, and 14). The function (chromium release assay) and number (flow cytometry) of natural killer (NK) cells were measured before operation (days -2 and -1), on the day of operation (day 0), and after operation (days 1, 2, 4, 6, and 18).


RESULTS
Surgical procedures suppressed NK cell cytotoxicity in the placebo group on postoperative days 1 (p < 0.001), 4, 6, and 18 (p < 0.05), whereas inhibition on postoperative day 2 failed to reach significance. PAPU abolished this immunosuppression after operation. The NK cell activity was elevated when compared with the control group; it was significant (p < 0.05) on postoperative days 1, 2, 4, 6, and 18. Surgical procedures also reduced circulating NK cell numbers during the first postoperative week in the placebo group; the decrease was statistically significant on day 4. The decrease in NK cell numbers in the PAPU group was insignificant.


CONCLUSIONS
PAPU prevented the decrease in the circulating number and cytotoxic activity of NK cells that occurred after operation and enhanced NK cell cytotoxicity. This may have important implications for patients with cancer undergoing major operation.
Khan
A L
AL
Department of Surgery, University of Aberdeen, Medical School, Scotland.
Richardson
S
S
Drew
J
J
Larsen
F
F
Campbell
M
M
Heys
S D
SD
Ah-See
A K
AK
Eremin
O
O
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000276:immunology / Q000601:surgery*; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D007694:Killer Cells, Natural / Q000276:immunology*; D008408:Mastectomy; D008875:Middle Aged; D011063:Poly A-U / Q000494:pharmacology*; D017452:Receptors, IgG / Q000032:analysis
D017452:Receptors, IgG; D011063:Poly A-U